Skip to main content
SpringerLink
Log in

Trandolapril/Verapamil Sustained Release

A Review of its Use in the Treatment of Essential Hypertension

  • Adis Drug Evaluation
  • Published:
Drugs Aims and scope Submit manuscript

Summary

Abstract

Trandolapril/verapamil sustained release (SR) [Tarka®] is an oral, fixed-dose combination of the ACE inhibitor trandolapril and the SR formulation of the phenylalkylamine calcium channel antagonist verapamil. It is indicated for the treatment of hypertension in patients who require more than one agent to achieve blood pressure (BP) targets. In the large, randomised, multicentre INVEST (INternational VErapamil SR/trandolapril STudy), a verapamil SR-based treatment strategy that included trandolapril in most patients was as effective as an atenolol-based treatment strategy in reducing the risk of the primary outcome (first occurrence of death [all-cause], nonfatal myocardial infarction [MI] or nonfatal stroke) in patients with hypertension and coronary artery disease (CAD) and was as well tolerated. Trandolapril/verapamil SR is generally more effective at controlling hypertension than either component as monotherapy, and is as effective as a number of other fixed-dose combination therapies. The combination is as well tolerated as trandolapril monotherapy and is at least as well tolerated as verapamil SR monotherapy. In hypertensive patients with type 2 diabetes mellitus in the BENEDICT (BErgamo NEphrologic DIabetes Complications Trial), trandolapril/verapamil SR prolonged the time to the onset of persistent microalbuminuria compared with placebo, as did trandolapril monotherapy. Thus, trandolapril/verapamil SR is an effective option for the treatment of essential hypertension in patients requiring more than one agent to achieve BP targets, including those with compelling indications, such as CAD or type 2 diabetes.

Pharmacological Properties

Trandolapril, a prodrug of the active metabolite trandolaprilat, reduces vasopressor activity and aldosterone release and provides negative feedback for renin secretion by inhibiting the conversion of angiotensin I to angiotensin II. The phenylalkylamine calcium channel antagonist verapamil causes dilation of peripheral and coronary vasculature, and thus a decrease in BP, by inhibiting the influx of calcium ions through the L-type calcium channels. Trandolapril/verapamil SR improves left ventricular (LV) wall structure and function in patients with hypertension and preserves LV function in patients with heart failure. Cardiac events are less common with trandolapril/verapamil SR than trandolapril monotherapy in patients with heart failure following an acute MI.

Peak plasma concentrations (Cmax) of trandolapril and trandolaprilat are achieved 0.5–1.5 and 3–12 hours after a single oral dose of trandolapril 2mg in healthy volunteers. The Cmax of trandolapril at steady state is double that after a single dose. Trandolapril is converted to trandolaprilat by hepatic metabolism. The absolute bioavailability of the parent drug is ≈10% and that of the active metabolite is 70%; both are highly protein-bound. The respective terminal elimination half-lives (t1/2β) of trandolapril and trandolaprilat are 6 and 10 hours, with the majority of a dose excreted in the faeces. Verapamil SR Cmax is achieved in ≈5 hours. Due to extensive first-pass metabolism in the liver, verapamil SR has an oral bioavailability of 10–35%. Verapamil is highly bound to plasma proteins. The primary metabolite of verapamil is the active desmethyl species, norverapamil. The SR formulation has a t1/2β of 8 hours after repeated administration, with the majority of a dose excreted in urine as metabolites.

There are no clinically relevant pharmacokinetic interactions between verapamil SR and trandolapril when the two agents are coadministered.

Therapeutic Efficacy

A verapamil SR-based treatment strategy in which most patients also received trandolapril was as effective as an atenolol-based treatment strategy at preventing the primary outcome (first occurrence of death [all-cause], nonfatal MI or nonfatal stroke) [9.9% vs 10.2%; mean follow-up 2.7 years] in patients with hypertension and CAD in the large (n = 22 576), randomised, multicentre INVEST. Similar proportions of patients receiving either treatment strategy achieved US Joint National Committee (JNC) VI BP targets (current consensus guidelines when INVEST was conducted) or BP control <140/90mm Hg.

In randomised, double-blind, multicentre studies (n > 100), trandolapril/verapamil SR 1mg/180mg, 2mg/180mg, 2mg/240mg or 4mg/240mg per day was more effective than placebo, and generally more effective than the corresponding dosages of trandolapril or verapamil SR monotherapy, at reducing mean sitting BP from baseline in adult patients with hypertension. The 1mg/180mg or 2mg/180mg dosages of trandolapril/verapamil SR were more effective at reducing mean 24-hour ambulatory systolic BP or diastolic BP than corresponding dosages of monotherapy. Trandolapril/verapamil SR was generally as effective at reducing BP as other fixed-dose combination therapies (metoprolol/hydrochlorothiazide, atenolol/chlortalidone, lisinopril/hydrochlorothiazide, enalapril/hydrochlorothiazide). Trandolapril/verapamil SR was effective at reducing mean sitting BP from baseline in patients unresponsive to either agent administered as monotherapy, and in special patient populations, such as Black or elderly patients or those with type 2 diabetes.

Compared with placebo, trandolapril/verapamil SR prolonged the time to onset of persistent microalbuminuria in patients with hypertension and type 2 diabetes in the large, double-blind, multicentre BENEDICT, as did trandolapril monotherapy.

Tolerability

Trandolapril/verapamil SR was generally well tolerated in clinical trials in patients with hypertension and had a tolerability profile similar to that of the individual components or respective class of drug. The incidence of adverse events (9–46%) and withdrawal rates due to adverse events (2.0–11.7%) in patients receiving trandolapril/verapamil SR was generally similar to that of comparator treatment arms. In INVEST, the verapamil SR-based and atenolol-based treatment strategies were equally well tolerated.

The most common adverse events occurring more frequently with trandolapril/verapamil SR than placebo were cough, first-degree atrioventricular block and constipation. Gastrointestinal tract adverse events and/or constipation were more likely with trandolapril/verapamil SR or verapamil SR than with trandolapril in two studies.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Table I
Table II
Table III
Fig. 1
Table IV
Table V
Fig. 2
Table VI
Fig. 3

Similar content being viewed by others

Notes

  1. The use of trade names is for product identification purposes only and does not imply endorsement.

References

  1. Wolf-Maier K, Cooper RS, Banegas JR, et al. Hypertension prevalence and blood pressure levels in 6 European countries, Canada, and the United States. JAMA 2003 May 14; 289(18): 2363–9

    Article  PubMed  Google Scholar 

  2. Chobanian AV, Bakris GL, Black HR, et al. The seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA 2003 May 21; 289(19): 2560–72

    Article  PubMed  CAS  Google Scholar 

  3. Guidelines Committee. 2003 European Society of Hypertension: European Society of Cardiology guidelines for the management of arterial hypertension. J Hypertens 2003; 21: 1011–53

    Article  Google Scholar 

  4. World Health Organization, International Society of Hypertension Writing Group. 2003 World Health Organization (WHO)/International Society of Hypertension (ISH) statement on management of hypertension. J Hypertens 2003; 21: 1983–92

    Article  Google Scholar 

  5. Williams B, Poulter NR, Brown MJ, et al. the BHS guidelines working party; for the British Hypertension Society. British Hypertension Society guidelines for hypertension management 2004 (BHS-IV): summary. Br Med J 2004 Mar 13; 328: 634–40

    Google Scholar 

  6. American Diabetes Association. Treatment of hypertension in adults with diabetes. Diabetes Care 2002 Jan; 25(1): 199–201

    Article  Google Scholar 

  7. Sica DA. Rationale for fixed-dose combinations in the treatment of hypertension: the cycle repeats. Drugs 2002; 62(3): 443–62

    Article  PubMed  CAS  Google Scholar 

  8. Abbott Laboratories, North Chicago (IL), USA. TARKA® (trandolapril/verapamil hydrochloride ER tablets): prescribing information 2003 [online]. Available from URL: http://www.abbott.com/corporate/product_list.cfm [Accessed 2005 Jan27]

  9. Muijsers RBR, Curran MP, Perry CM. Fixed combination trandolapril/verapamil sustained-release: a review of its use in essential hypertension. Drugs 2002; 62(17): 2539–67

    Article  PubMed  CAS  Google Scholar 

  10. Breithaupt-Grögler K, Gerhardt G, Lehmann G, et al. Blood pressure and aortic elastic properties: verapamil SR/trandolapril compared to a metoprolol/hydrochlorothiazide combination therapy. Int J Clin Pharmacol Ther 1998 Aug; 36(8): 425–31

    PubMed  Google Scholar 

  11. de Leeuw PW, Notter T, Zilles P. Comparison of different fixed antihypertensive combination drugs: a double-blind, placebo-controlled parallel group study. J Hypertens 1997 Jan; 15(1): 87–91

    Article  PubMed  Google Scholar 

  12. Viskoper RJ, Compagnone D, Dies R, et al. Verapamil and trandolapril alone and in fixed combination on 24-hour ambulatory blood pressure profiles of patients with moderate essential hypertension. Curr Ther Res Clin Exp 1997 Jun; 58(6): 343–51

    Article  CAS  Google Scholar 

  13. Topouchian J, Asmar R, Sayegh F, et al. Changes in arterial structure and function under trandolapril-verapamil combination in hypertension. Stroke 1999 May; 30(5): 1056–64

    Article  PubMed  CAS  Google Scholar 

  14. Ramos F, Baglivo H, Sánchez R. Comparative double blind study at fixed dose of trandolapril + verapamil vs. atenolol + chlortalidone in mild to moderate hypertensive patients [abstract no. P3.185]. J Hypertens 2001 Jun; 19 Suppl. 2: S236

    Google Scholar 

  15. Aepfelbacher FC, Messerli FH, Nunez E, et al. Cardiovascular effects of a trandolapril/verapamil combination in patients with mild to moderate essential hypertension. Am J Cardiol 1997 Mar 15; 79(6): 826–8

    Article  PubMed  CAS  Google Scholar 

  16. Adalet K, Oflaz H, Sezer A, et al. on behalf of the Working Group on Verapamil-Trandolapril Combination Therapy in Essential Hypertension. Efficacy and tolerability of fixed, low-dose combination therapy with verapamil sustained-release and trandolapril in patients with mild to severe essential hypertension uncontrolled by monotherapy: an open-label, multicentre trial. Curr Ther Res Clin Exp 2001 Apr; 62(4): 261–71

    CAS  Google Scholar 

  17. Mitrovic V, Parzeller M, Notter T, et al. Antihypertensive combination treatment with verapamil SR 180 mg/trandolapril 2 mg preserves left ventricular function in NYHA class I and II heart failure patients [abstract no 143]. Cardiovasc Drugs Ther 1999 Mar; 13(1): 38

    Google Scholar 

  18. Hansen JF, Hagerup L, Sigurd B, et al. Cardiac event rates after acute myocardial infarction in patients treated with verapamil and trandolapril versus trandolapril alone. Am J Cardiol 1997 Mar 15; 79: 738–41

    Article  PubMed  CAS  Google Scholar 

  19. Cifková R, Nakov R, Novozámská E, et al. Evaluation of the effects of fixed combinations of sustained-release verapamil/trandolapril versus captopril/hydrochlorothiazide on metabolic and electrolyte parameters in patients with essential hypertension. J Hum Hypertens 2000 Jun; 14(6): 347–54

    Article  PubMed  Google Scholar 

  20. Fernández R, Puig JG, Rodríguez-Pérez JC, et al. on behalf of the TRAVEND Study Group. Effect of two antihypertensive combinations on metabolic control in type-2 diabetic hypertensive patients with albuminuria: a randomised, double-blind study. J Hum Hypertens 2001 Dec; 15(12): 849–56

    Google Scholar 

  21. Schneider M, Lerch M, Papiri M, et al. Metabolic neutrality of combined verapamil-trandolapril treatment in contrast to beta-blocker-low-dose chlortalidone treatment in hypertensive type 2 diabetes. J Hypertens 1996 May; 14(5): 669–77

    Article  PubMed  CAS  Google Scholar 

  22. Abbott Laboratories. Tarka 180/2mg capsules: summary of product characteristics 2002 [online]. Available from URL: http://emc.medicines.org.uk/ [Accessed 2005 Jan 25]

  23. Sweetman S, editor. Martindale: the complete drug reference. London: Pharmaceutical Press. Electronic Version, (2005). Dantrolene sodium [online]. Available from: http://www.medicinescomplete.com/mc/martindales [Accessed 2005 Apr 26]

  24. Danielson B, Querin S, LaRochelle P, et al. Pharmacokinetics and pharmacodynamics of trandolapril after repeated administration of 2 mg to patients with chronic renal failure and healthy control subjects. J Cardiovasc Pharmacol 1994; 23 Suppl. 4: S50–9

    PubMed  Google Scholar 

  25. Lenfant B, Mouren M, Bryce T, et al. Trandolapril: pharmacokinetics of single oral doses in healthy male volunteers. J Cardiovasc Pharmacol 1994; 23 Suppl. 4: S38–43

    PubMed  CAS  Google Scholar 

  26. Siepmann M, Rao BR, Kirch W. Disposition, elimination and haemodynamic effects of verapamil and trandolapril in patients with fatty liver disease. Clin Drug Invest 1997 Nov; 14(5): 376–32

    Article  CAS  Google Scholar 

  27. Wiseman LR, McTavish D. Trandolapril: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in essential hypertension. Drugs 1994 Jul; 48(1): 71–90

    Article  PubMed  CAS  Google Scholar 

  28. Peters DC, Noble S, Plosker GL. Trandolapril: an update of its pharmacology and therapeutic use in cardiovascular disorders. Drugs 1998 Nov; 56(5): 871–93

    Article  PubMed  CAS  Google Scholar 

  29. McTavish D, Sorkin EM. Verapamil: an updated review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in hypertension. Drugs 1989 Jul; 38(1): 19–76

    Article  PubMed  CAS  Google Scholar 

  30. Brogden RN, Benfield P. Verapamil: a review of its pharmacological properties and therapeutic use in coronary artery disease. Drugs 1996 May; 51(5): 792–819

    Article  PubMed  CAS  Google Scholar 

  31. Abbott Laboratories. Isoptin SR (verapamil HCL) US prescribing information. North Chicago (IL): Abbott Laboratories, 2002

    Google Scholar 

  32. Abbott Laboratories, North Chicago (IL), USA. Mavik® (trandolapril tablets) prescribing information 2003 [online]. Available from URL: http://www.rxabbott.com/pdf/mavik.pdf [Accessed 2005 May 2]

  33. Pepine CJ, Handberg-Thurmond E, Marks RG, et al. Rationale and design of the International Verapamil SR/Trandolapril Study (INVEST): an Internet-based randomised trial in coronary artery disease patients with hypertension. J Am Coll Cardiol 1998 Nov; 32(5): 1228–37

    Article  PubMed  CAS  Google Scholar 

  34. Pepine CJ, Handberg EM, Cooper-DeHoff RM, et al. for the INVEST Investigators. A calcium antagonist vs a non-calcium antagonist hypertension treatment strategy for patients with coronary artery disease. The International Verapamil-Trandolapril Study (INVEST): a randomised controlled trial. JAMA 2003 Dec 3; 290(21): 2805–16

    CAS  Google Scholar 

  35. DeQuattro V, Lee D, and the Trandolapril Study Group. Fixed-dose combination therapy with trandolapril and verapamil SR is effective in primary hypertension. Am J Hypertens 1997 Jul; 10 (7 Pt 2): 138S–45S

    Article  PubMed  CAS  Google Scholar 

  36. DeQuattro V, Lee D, Messerli F, and the Trandolapril Study Group. Efficacy of combination therapy with trandolapril and verapamil SR in primary hypertension: a 4 × 4 trial design. Clin Exp Hypertens 1997 Apr; 19(3): 373–87

    Article  PubMed  CAS  Google Scholar 

  37. Karlberg BE, Andrup M, Odén A, on behalf of the Swedish Tarka trialists. Efficacy and safety of a new long-acting drug combination, trandolapril/verapamil as compared to monotherapy in primary hypertension. Blood Press 2000; 9(2–3): 140–5

    Article  PubMed  CAS  Google Scholar 

  38. Messerli F, Frishman WH, Elliott WJ, for the Trandolapril Study Group. Effects of verapamil and trandolapril in the treatment of hypertension. Am J Hypertens 1998 Mar; 11 (3 Pt 1): 322–7

    Article  PubMed  CAS  Google Scholar 

  39. Scholze J, Zilles P, Compagnone D, on behalf of the German Hypertension Study Group. Verapamil SR and trandolapril combination therapy in hypertension: a clinical trial of factorial design. Br J Clin Pharmacol 1998 May; 45(5): 491–5

    Article  PubMed  CAS  Google Scholar 

  40. The Veratran Study Group. Effects of verapamil SR, trandolapril, and their fixed combination on 24-h blood pressure: the Veratran Study. Am J Hypertens 1997 May; 10 (5 Pt 1): 492–9

    Article  Google Scholar 

  41. Viskoper RJ, Compagnone D, Dies R, et al. Verapamil and trandolapril alone and in fixed combination in moderate essential hypertension: a multicentre, double-masked study. Curr Ther Res Clin Exp 1997 Jun; 58(6): 331–42

    Article  CAS  Google Scholar 

  42. Beevers DG, Gallet M, Middeke M, et al. Efficacy and safety of the fixed combination verapamil SR/trandolapril 180/2 mg in hypertensive patients insufficiently pretreated with trandolapril 2 mg monotherapy [abstract no. E019]. Am J Hypertension 1998; 11 (4 Pt 2): 100a

    Article  Google Scholar 

  43. Sever PS, de Chatel R, Cifkova R, et al. Antihypertensive efficacy and safety of verapamil SR /trandolapril (240/2 mg) in patients insufficiently pretreated with verapamil SR 240 mg monotherapy [abstract no. D097]. Am J Hypertens 1999 Apr; 12 (4 Pt 2): 135A

    Article  Google Scholar 

  44. Ruilope LM, Usan L, Segura J, et al. Intervention at lower blood pressure levels to achieve target goals in type 2 diabetes: PRADID (PResión Arterial en DIabéticos tipo Dos) study. J Hypertens 2004; 22(1): 217–22

    Article  PubMed  CAS  Google Scholar 

  45. Punzi HA, Novrit BA, for the Trandolapril/Verapamil multicentre Study Group. The treatment of severe hypertension with trandolapril, verapamil, and hydrochlorothiazide. J Hum Hypertens 1997 Aug; 11(8): 477–81

    Article  PubMed  CAS  Google Scholar 

  46. Skoularigis J, Strugo V, Radevski I, et al. Once-daily fixed dose combinations of verapamil and trandolapril in Black patients with mild to moderate hypertension: a new choice for first line treatment. Int J Clin Pharmacol Ther 1997 Feb; 35(2): 51–5

    PubMed  CAS  Google Scholar 

  47. Holzgreve H, Compagnone D, Zilles P, on behalf of the German VeraTran Hypertension Study Group. Verapamil SR/trandolapril combination therapy for the elderly hypertensive patient. J Hum Hypertens 1999 Jan; 13(1): 61–7

    Article  PubMed  CAS  Google Scholar 

  48. Bakris GL, Weir MR, DeQuattro V, et al. Effects of an ACE inhibitor/calcium antagonist combination on proteinuria in diabetic nephropathy. Kidney Int 1998 Oct; 54(4): 1283–9

    Article  PubMed  CAS  Google Scholar 

  49. Rubio-Guerra AF, Treviño-Gomezharper C, Rodríguez-López L, et al. Renoprotective effects of the combination trandolapril/verapamil in patients with type 2 diabetes and hypertension. Clin Drug Invest 2002; 22(8): 541–6

    Article  CAS  Google Scholar 

  50. Ruggenenti P, Fassi A, Parvanova Ilieva A, et al. for the Bergamo Nephrologic Diabetes Complications Trial (BENEDICT) Investigators. Preventing microalbuminuria in type 2 diabetes. N Engl J Med 2004 Nov 4; 351(19): 1941–51

    CAS  Google Scholar 

  51. Bakris GL, Gaxiola E, Messerli FH, et al. Clinical outcomes in the diabetes cohort of the INternational VErapamil SR-Trandolapril study. Hypertension 2004 Nov; 44(5): 637–42

    Article  PubMed  CAS  Google Scholar 

  52. Cooper-DeHoff RM, Kolloch R, Messerli FH, et al. Blood pressure control, angina episodes, and cardiovascular outcomes in patients with ischemia: the International Verapamil/Trandolapril Study [abstract no. 1085-197]. J Am Coll Cardiol 2004 Mar 3; 43 (5 Suppl. A): 483A. Plus poster presented at the 53rd Annual Scientific Sessions of the American College of Cardiologists; 2004 Mar 7–10; New Orleans (LA)

    Article  Google Scholar 

  53. Mancia G, Cooper-DeHoff RM, Hewkin A, et al. Association of BP control and frequency of mortality and morbidity in hypertensive patients with CAD: the International Verapamil SR-Trandolapril study [abstract no. P-229]. Am J Hypertens 2004; 15 (5 Pt 2): 116a

    Article  Google Scholar 

  54. Gaxiola E, Zhou Q, Kupfer S, et al. Impact of antihypertensive therapy on the incidence of coronary revascularization in high-risk patients: the International Verapamil SR-Trandolapril Study (INVEST) [poster no. 1014-137]. 54th Annual Scientific Sessions of the American College of Cardiologists; 2005 Mar 6–9; Orlando (FL)

  55. Jamerson K, Champion A, Zhou Q, et al. Verapamil- and atenolol-based strategies are equally effective in black patients with hypertension and coronary artery disease: a subanalysis of the International VErapamil SR-Trandolapril study (INVEST) [abstract no. P286]. Am J Hypertens 2005; 18 (5 Suppl.): A109

    Article  Google Scholar 

  56. Ried LD, Tueth MJ, Handberg E, et al. A Study of Antihypertensive Drugs and Depressive Symptoms (SADD-Sx) in patients treated with a calcium antagonist versus an atenolol hypertension Treatment Strategy in the International Verapamil SR-Trandolapril Study (INVEST). Psychosom Med 2005 May; 67(3): 398–406

    Article  PubMed  CAS  Google Scholar 

  57. Cooper-DeHoff RM, Handberg EM, Cohen J, et al. Characteristics of contemporary patients with hypertension and coronary artery disease. Clin Cardiol 2004 Oct; 27(10): 571–6

    Article  PubMed  Google Scholar 

  58. Brewster LM, van Montfrans GA, Kleijnen J. Systematic review: antihypertensive drug therapy in Black patients. Ann Intern Med 2004 Oct 19; 141(8): 614–27

    PubMed  Google Scholar 

  59. Holzgreve H. Safety profile of the combination of verapamil and trandolapril. J Hypertens 1997 Mar; 15 Suppl. 2: S51–3

    CAS  Google Scholar 

  60. Abbott Laboratories, Switzerland. Tarka®: kombiniertes antihypertonikum kombination ACE-hemmer/nicht-dihydropyridin-calciumanatgonist. Switzerland, 2004 Aug

  61. Abbott Laboratories, France. Resume des caracteristiques du produit: Tarka LP. France, 2004 Aug

  62. Grundy SM, Hansen B, Smith Jr SC, et al. for Conference Participants. Clinical management of metabolic syndrome: report of the American Heart Association/National Heart, Lung, and Blood Institute/American Diabetes Association Conference on scientific issues related to management. Circulation 2004 Feb 3; 109(4): 551–6

    Google Scholar 

  63. Williams B. Recent hypertension trials: implications and controversies. J Am Coll Cardiol 2005; 45(6): 813–7

    Article  PubMed  Google Scholar 

  64. Pepine CJ, Conti CR. Managing hypertension in European patients with coronary artery disease: design, results, and clinical implications of INVEST. Ital Heart J 2004 Jun; 5(6): 411–6

    PubMed  Google Scholar 

  65. Joint National Committee on Prevention, Detection, Evaluation and Treatment of High Blood Pressure: the National High Blood Pressure Education Program Coordinating Committee. The sixth report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Arch Intern Med 1997 Nov 24; 157: 2413–46

    Article  Google Scholar 

  66. Pepine CJ, Cooper-DeHoff RM. Cardiovascular therapies and the risk of developing diabetes. Journal of the American College of Cardiologists 2004; 44(3): 509–12

    Article  CAS  Google Scholar 

  67. Jandeleit-Dahm KAM, Tikellis C, Reid CM, et al. Why blockade of the renin-angiotensin system reduces the incidence of new-onset diabetes. J Hypertens 2005; 23: 463–73

    Article  PubMed  CAS  Google Scholar 

  68. Opie LH, Schall R. Old hypertensives and new diabetes. J Hypertens 2004; 22: 1453–8

    Article  PubMed  CAS  Google Scholar 

  69. Faulkner MA, Hilleman DE. Fixed-dose combination antihypertensive therapy with trandolapril/verapamil: a metaanalytic comparison against monotherapy. Am J Hypertens 2004 May 2; 17(5): 105

    Google Scholar 

  70. American Diabetes Association. Diabetic nephropathy. Diabetes Care 2002 Jan; 25 Suppl. 1: S85–9

    Article  Google Scholar 

  71. Joyce AT, Pedan A, Girase PS, et al. Economic impact of selected fixed-combination angiotensin-converting enzyme inhibitor/calcium channel blocker anti-hypertensives among patients with diabetes [abstract no PCV58]. Value Health 2003 Nov; 6(6): 665. Plus poster presented at the 6th Annual European Congress of the International Society for Pharmacoeconomics and Outcome Research; 2003 Nov 9–11; Barcelona

    Article  Google Scholar 

  72. Nuijten M, Wittenberg W, Kosa J. The cost-effectiveness of Tarka for preventing renal failure in type 2 diabetic patients with hypertension in the US health care setting [abstract no. PDB19]. Value Health 2003; 6(3): 334

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Adis International Limited, 41 Centorian Drive, Private Bag 65901, Mairangi Bay, Auckland, 1311, New Zealand

    Neil A. Reynolds, Antona J. Wagstaff & Susan J. Keam

Authors
  1. Neil A. Reynolds
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Antona J. Wagstaff
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Susan J. Keam
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Susan J. Keam.

Additional information

Various sections of the manuscript reviewed by: G. Bakris, Department of Preventative and Internal Medicine, Rush Presbyterian St Lukes Medical Center/Rush Medical College, Chicago, Illinois, USA; P.W. de Leeuw, Department of Medicine, University Hospital Maastricht, Maastricht, The Netherlands; C.J. Pepine, Division of Cardiovascular Medicine, University of Florida College of Medicine, Gainesville, Florida, USA; H.A. Punzi, Trinity Hypertension Research Center, Trinity Medical Center, Carrollton, Texas, USA; A.F. Rubio-Guerra, Hypertension Clinic, Hospital General de Ticoman SS, Mexico City, Mexico; P. Ruggenenti, Clinical Research Centre for Rare Diseases, Mario Negri Institute for Pharmacological Research, Milan, Italy; J. Segura, Hospital 12 de Octubre, Madrid, Spain; M.R. Weir, Division of Nephrology, University of Maryland School of Medicine, Baltimore, Maryland, USA.

Data Selection

Sources: Medical literature published in any language since 1980 on trandolapril/verapamil, identified using MEDLINE and EMBASE, supplemented by AdisBase (a proprietary database of Adis International). Additional references were identified from the reference lists of published articles. Bibliographical information, including contributory unpublished data, was also requested from the company that markets the drug.

Search strategy: MEDLINE, EMBASE and AdisBase search terms were ‘trandolapril/verapamil’ or ‘trandolapril plus verapamil’. Searches were last updated 7 June 2005.

Selection: Studies in patients with hypertension who received trandolapril/verapamil sustained release. Inclusion of studies was based mainly on the methods section of the trials. When available, large, well controlled trials with appropriate statistical methodology were preferred. Relevant pharmacodynamic and pharmacokinetic data are also included.

Index terms: Trandolapril, verapamil, verapamil SR, trandolapril/verapamil SR, coronary artery disease, hypertension, pharmacodynamics, pharmacokinetics, therapeutic use.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Reynolds, N.A., Wagstaff, A.J. & Keam, S.J. Trandolapril/Verapamil Sustained Release. Drugs 65, 1893–1914 (2005). https://doi.org/10.2165/00003495-200565130-00011

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00003495-200565130-00011

Keywords

Search

Navigation